Table 3

Utilization and cost of diabetes testing supplies by Type of Diabetes and Treatment, Saskatchewan 2001


Number of Cases
Number (%) of Subjects with ≥ 1 record for testing supplies
Average (SD) Number of Records
Average (SD) DP share (Can$)
Average (SD) Patient Share (Can$)
Average (SD)A, B Total (Can$)

Type 1
4005
3143 (78.5)
5.8 (6.4)
231.71 (408.53)A
240.60 (343.81)A
472.31 (560.75)A
          (% of Total)
(9.6%)


(49.1%)
(50.9%)

Type 2






     No medication
14157
3169 (22.4%)
0.5 (1.5)
11.78 (62.14)B
23.69 (72.61)B
35.47 (107.22)B
          (% of Type 2)
(37.6%)


(33.2%)
(66.8%)

     Oral anti-diabetic agent only
18910
11814 (62.5)
2.0 (2.6)
57.78 (132.42)
73.42 (110.65)
131.21 (189.78)
          (% of Type 2)
(50.3%)


(44.0%)
(56.0%)

     Insulin only
2212
1751 (79.2)
4.6 (5.0)
194.53 (296.40)
153.33 (233.26)
347.86 (409.39)
          (% of Type 2)
(5.9%)


(55.9%)
(44.1%)

     Insulin and oral anti-diabetic agent
2346
2037 (86.8)
4.9 (4.4)
220.08 (286.55)
148.48 (187.50)
368.56 (362.67)
          (% of Type 2)
(6.2%)


(59.7%)
(40.3%)

Type 2 Total
37625
18771 (49.9)
1.8 (2.9)
58.63 (155.18)A
64.09 (122.86)A
122.72 (233.88)A
          (% of Total)
(90.4%)


(47.8%)
(52.2%)


A p < 0.001 between type 1 and type 2 diabetes using the Kruskal Wallis Test

B p < 0.001 between treatment groups within type 2 diabetes (i.e. no medication, oral anti-diabetic agent only, insulin only, insulin and oral anti-diabetic agent) using the Kruskal Wallis Test

Johnson et al. BMC Health Services Research 2006 6:159   doi:10.1186/1472-6963-6-159